📰 Primary Biliary News
Page 2 - Primary Biliary News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Primary Biliary. Real-time updates on events, politics, business and more.
December 15, 2023
The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.
December 15, 2023
CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
September 8, 2023
Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.
June 7, 2023
Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,... | June 7, 2023
June 7, 2023
Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis).
May 12, 2023
Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq
May 11, 2023
Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille ; Cambridge, ; Zurich ; May 11, 2023 - GENFIT , a late-stage biopharmaceutical company... | May 11, 2023
April 20, 2023
Organ donation saves lives, even as the donor loses theirs. April is National Donate Life Month. It’s designed to encourage people to register to be organ donors and to talk to their families about it. But few people outside of hospital staff see the process in action.I’ve recently been spending
October 31, 2022
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis... | October 31, 2022
May 10, 2022
(BPT) - Do you have primary biliary cholangitis or know somebody who does? If so, you know that people living with PBC, a chronic, serious and potentially life-threatening liver disease,